TipRanks
Advertisement
Advertisement

IRD Stock Latest News

Opus Genetics reports FDA approval of phentolamine ophthalmic solution 0.75%
The FlyOpus Genetics reports FDA approval of phentolamine ophthalmic solution 0.75%
6h ago
IRD
VTRS
Opus Genetics Advances Gene Therapy Programs With New Data
PremiumCompany Announcements
Opus Genetics Advances Gene Therapy Programs With New Data
1d ago
8K
IRD
Opus Genetics presents clinical findings from its OPGx-BEST1, OPGx-LCA5 programs
PremiumThe Fly
Opus Genetics presents clinical findings from its OPGx-BEST1, OPGx-LCA5 programs
1d ago
IRD
Opus Genetics management to meet with Oppenheimer
PremiumThe Fly
Opus Genetics management to meet with Oppenheimer
4d ago
IRD
Opus Genetics price target raised to $17 from $10 at Jones
PremiumThe Fly
Opus Genetics price target raised to $17 from $10 at Jones
11d ago
IRD
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook
PremiumCompany AnnouncementsOpus Genetics Updates OPGx-BEST1 Trial Data and Outlook
1M ago
8K
IRD
Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress
Premium
Ratings
Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress
1M ago
IRD
Opus Genetics price target raised to $14 from $11 at Leerink
Premium
The Fly
Opus Genetics price target raised to $14 from $11 at Leerink
1M ago
IRD
Opus Genetics price target raised to $20 from $10 at Oppenheimer
PremiumThe Fly
Opus Genetics price target raised to $20 from $10 at Oppenheimer
1M ago
IRD
Opus Genetics price target raised to $16 from $13 at Chardan
PremiumThe Fly
Opus Genetics price target raised to $16 from $13 at Chardan
1M ago
IRD
Yun Zhong Reiterates Buy on Opus Genetics, Lifts Price Target to $13 on Higher Probability of Success for OPGx-BEST1 Program
PremiumRatings
Yun Zhong Reiterates Buy on Opus Genetics, Lifts Price Target to $13 on Higher Probability of Success for OPGx-BEST1 Program
1M ago
IRD
Midday Fly By: Analog acquires Alif, Independence Realty merges with Centerspace
PremiumThe Fly
Midday Fly By: Analog acquires Alif, Independence Realty merges with Centerspace
1M ago
BP
ADI
Opus: Encouraging BIRD-1 Data, Expanded BEST1 Opportunity and Solid Cash Position Support Maintained Buy Rating and Unchanged $10 Price Target
PremiumRatingsOpus: Encouraging BIRD-1 Data, Expanded BEST1 Opportunity and Solid Cash Position Support Maintained Buy Rating and Unchanged $10 Price Target
1M ago
IRD
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data
Premium
Company Announcements
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data
1M ago
8K
IRD
Opus Genetics announces results from low-dose Cohort 1 of BIRD-1 trial
Premium
The Fly
Opus Genetics announces results from low-dose Cohort 1 of BIRD-1 trial
1M ago
IRD
Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained
PremiumRatings
Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained
2M ago
IRD
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
PremiumThe Fly
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
2M ago
IRD
LGVN
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
PremiumRatings
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
2M ago
IRD
Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target
PremiumRatings
Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target
2M ago
IRD
Opus Genetics price target lowered to $9 from $10 at RBC Capital
PremiumThe FlyOpus Genetics price target lowered to $9 from $10 at RBC Capital
2M ago
IRD
Opus Genetics files $300M mixed securities shelf
Premium
The Fly
Opus Genetics files $300M mixed securities shelf
2M ago
IRD
Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028
Premium
Ratings
Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028
2M ago
IRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >